Hyundai Bioscience Co., Ltd. (048410.KQ)
KRW 13990.0
(-1.82%)
KRW 13990.0
(-1.82%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 5.54 Billion KRW | -11.24% |
| 2022 | 6.24 Billion KRW | -59.65% |
| 2021 | 15.48 Billion KRW | -58.3% |
| 2020 | 37.13 Billion KRW | 174.96% |
| 2019 | 13.5 Billion KRW | 45.22% |
| 2018 | 9.3 Billion KRW | -43.32% |
| 2017 | 16.41 Billion KRW | -40.0% |
| 2016 | 27.35 Billion KRW | 104.09% |
| 2015 | 13.4 Billion KRW | 173.51% |
| 2014 | 4.9 Billion KRW | -2.83% |
| 2013 | 5.04 Billion KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 5.86 Billion KRW | 6.3% |
| 2024 Q1 | 5.51 Billion KRW | -0.5% |
| 2023 Q4 | 5.54 Billion KRW | -7.41% |
| 2023 FY | 5.54 Billion KRW | -11.24% |
| 2023 Q1 | 6.17 Billion KRW | -1.24% |
| 2023 Q2 | 5.63 Billion KRW | -8.74% |
| 2023 Q3 | 5.99 Billion KRW | 6.37% |
| 2022 Q4 | 6.24 Billion KRW | -11.39% |
| 2022 Q1 | 7.57 Billion KRW | -51.11% |
| 2022 Q2 | 7.3 Billion KRW | -3.59% |
| 2022 Q3 | 7.05 Billion KRW | -3.41% |
| 2022 FY | 6.24 Billion KRW | -59.65% |
| 2021 Q3 | 20.25 Billion KRW | -47.13% |
| 2021 FY | 15.48 Billion KRW | -58.3% |
| 2021 Q1 | 37.65 Billion KRW | 2.41% |
| 2021 Q2 | 38.31 Billion KRW | 1.76% |
| 2021 Q4 | 15.48 Billion KRW | -23.55% |
| 2020 Q4 | 36.76 Billion KRW | 5.91% |
| 2020 FY | 37.13 Billion KRW | 174.96% |
| 2020 Q2 | 8.64 Billion KRW | 47.47% |
| 2020 Q1 | 5.86 Billion KRW | -55.57% |
| 2020 Q3 | 34.71 Billion KRW | 301.59% |
| 2019 Q3 | 13.25 Billion KRW | -17.65% |
| 2019 FY | 13.5 Billion KRW | 45.22% |
| 2019 Q4 | 13.19 Billion KRW | -0.45% |
| 2019 Q2 | 16.09 Billion KRW | 5.7% |
| 2019 Q1 | 15.22 Billion KRW | 65.96% |
| 2018 Q1 | 15.94 Billion KRW | -2.62% |
| 2018 FY | 9.3 Billion KRW | -43.32% |
| 2018 Q4 | 9.17 Billion KRW | -16.22% |
| 2018 Q3 | 10.94 Billion KRW | -33.17% |
| 2018 Q2 | 16.38 Billion KRW | 2.72% |
| 2017 Q4 | 16.37 Billion KRW | -7.64% |
| 2017 FY | 16.41 Billion KRW | -40.0% |
| 2017 Q1 | 26.55 Billion KRW | -2.8% |
| 2017 Q2 | 21.52 Billion KRW | -18.94% |
| 2017 Q3 | 17.73 Billion KRW | -17.61% |
| 2016 FY | 27.35 Billion KRW | 104.09% |
| 2016 Q2 | 16.37 Billion KRW | -0.49% |
| 2016 Q3 | 23.49 Billion KRW | 43.44% |
| 2016 Q4 | 27.31 Billion KRW | 16.29% |
| 2016 Q1 | 16.45 Billion KRW | 23.1% |
| 2015 Q3 | 5.22 Billion KRW | -16.81% |
| 2015 Q4 | 13.36 Billion KRW | 156.1% |
| 2015 Q2 | 6.27 Billion KRW | -13.22% |
| 2015 Q1 | 7.23 Billion KRW | 47.56% |
| 2015 FY | 13.4 Billion KRW | 173.51% |
| 2014 Q2 | 4.91 Billion KRW | 0.15% |
| 2014 Q3 | 4.9 Billion KRW | -0.23% |
| 2014 Q1 | 4.91 Billion KRW | -2.61% |
| 2014 Q4 | 4.9 Billion KRW | -0.15% |
| 2014 FY | 4.9 Billion KRW | -2.83% |
| 2013 FY | 5.04 Billion KRW | 0.0% |
| 2013 Q1 | 8.34 Billion KRW | 0.0% |
| 2013 Q2 | 6.42 Billion KRW | -22.92% |
| 2013 Q4 | 5.04 Billion KRW | -6.91% |
| 2013 Q3 | 5.41 Billion KRW | -15.74% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 53.62 Billion KRW | 89.657% |
| ST Pharm Co.,Ltd. | 192.08 Billion KRW | 97.112% |
| ABL Bio Inc. | 43.93 Billion KRW | 87.376% |
| Cellid, Co., Ltd. | 11.99 Billion KRW | 53.759% |